

71. The method of claim 69 wherein the kringle region fragment comprises a majority of kringle 5.

RECEIVED

72. (new) The method of claim 69 wherein the kringle region fragment results from a cleavage after amino acid residue number 529 or 530 of plasminogen. FEB 2 6 2001 TECH CENTER 1600/2900


73. (new) A method of treating an angiogenesis-mediated disease in an individual comprising, increasing in the individual *in vivo* concentrations of a kringle region fragment of a plasminogen molecule to an angiogenesis inhibiting amount, wherein the kringle region fragment has anti-angiogenic activity *in vivo*.

74. (new) The method of claim 73 wherein the kringle region fragment comprises a majority of kringle 5.

75. (new) The method of claim 73 wherein the kringle region fragment results from a cleavage after amino acid residue number 529 or 530 of plasminogen. --


REMARKS

Claims 1-58 were formerly pending. Claims 59-75 have been added. Thus, claims 1-75 are now pending and presented for examination. The new claims are fully supported by the specification as originally filed and therefore contain no new matter. Specifically, claim 59 is supported by the specification at page 4, lines 8-17; page 12, line 21 to page 13, line 14; page 13, lines 20-26; page 18 line 22 to page 19, line 25; and page 39, line 25 to page 41, line 2. Claims 60 and 61 are supported by the specification at page 2, lines 19-20; page 14, lines 6-9; and page 35, line 25 to page 39, line 30. Claim 62 is supported by the specification at page 31, lines 16-20; page 34, line 5 to page 35, line 16; and page 40, line 1 to page 41, line 2. Claims 63 and 64 are supported by the specification at page 2, lines 19-20; page 14, lines 6-9; and page 35, line 25 to page 39, line 30. Claim 65 is supported by the specification at page 4, lines 8-17; page 12, line 21 to page 13, line 14; page 13, lines 20-26; page 18 line 22 to page 19, line 25; page 39, line 25 to page 41, line 2. Claim 66 is supported by the specification at page 2, lines 19-20; page 14, lines 6-9; and page 35, line 25 to page 39, line 30. Claim 67 is supported by the specification at page 31, lines 16-20; page 34, line 5 to page 35, line 16; page 40, line 1 to page 41, line 2.



RECEIVED

FEB 26 2001



TECH CENTER 1600/2900


Claim 68 is supported by the specification at page 2, lines 19-20; page 14, lines 6-9; and page 35, line 25 to page 39, line 30. Claim 69 is supported by the specification at page 3, lines 24-28; page 18, line 22 to page 19, line 3; page 19, lines 4-25; page 26, lines 4-12; page 26 line 26 to page 27, line 5; page 44, line 15 to page 45, line 29; page 48, line 5 to page 50, line 17; and Table 1, page 51. Claim 70 is supported by the specification at page 2, lines 19-20; page 14, lines 6-9; and page 35, line 25 to page 39, line 30. Claims 71 and 72 are supported by the specification at page 12, line 21 to page 14, line 5. Claim 73 is supported by the specification at page 3, lines 24-28; page 18, line 22 to page 19, line 3; page 19, lines 4-25; page 26, lines 4-12; page 26 line 26 to page 27, line 5; page 44, line 15 to page 45, line 29; page 48, line 5 to page 50, line 17; and Table 1, page 51. Claim 74 is supported by the specification at page 12, line 21 to page 14, line 5; and claim 75 is supported by the specification at page 12, line 21 to page 14, line 5. The Examiner's attention is invited to U.S. Patent No. 6,024,688 and in particular to claims 1, 4, 41, 45, and 47.

CONCLUSION

Entry of the above amendments and consideration of the above remarks is requested. No fee is believed to be due other than the fee for the claims added in this amendment. If any other fee is due, please charge the required amount to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: February 15, 2001


Laura A. Coruzzi

30,742

(Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

Enclosures